University of Minnesota · Jan 2026
University of Minnesota highlighted a chemistry publication on YCT-529 and noted that the program was advancing in a phase 2a clinical trial in New Zealand.
YourChoice therapeutics is revolutionizing the contraceptive market…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Clinical-stage biotechnology company developing hormone-free, oral male contraception; its lead asset YCT-529 is a reversible retinoic acid receptor-alpha (RAR-alpha) antagonist being evaluated in human clinical trials.
Primary product
YCT-529, a hormone-free oral male contraceptive pill
Founded
2018
Headquarters
Berkeley, California, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Reproductive health / contraceptive biopharma
Offices
Berkeley, CA (HQ)
Open Positions
0 jobs at YourChoice Therapeutics
No open positions
Check back later for new openings